320 related articles for article (PubMed ID: 18627414)
1. The clinical impact of pharmacogenetics on the treatment of epilepsy.
Löscher W; Klotz U; Zimprich F; Schmidt D
Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
[TBL] [Abstract][Full Text] [Related]
3. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.
Dorado P; López-Torres E; Peñas-Lledó EM; Martínez-Antón J; Llerena A
Pharmacogenomics J; 2013 Aug; 13(4):359-61. PubMed ID: 22641027
[TBL] [Abstract][Full Text] [Related]
4. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetic criteria of drug-resistant epilepsy].
Oros MM
Lik Sprava; 2012 Dec; (8):71-4. PubMed ID: 23786015
[TBL] [Abstract][Full Text] [Related]
6. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Tate SK; Depondt C; Sisodiya SM; Cavalleri GL; Schorge S; Soranzo N; Thom M; Sen A; Shorvon SD; Sander JW; Wood NW; Goldstein DB
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5507-12. PubMed ID: 15805193
[TBL] [Abstract][Full Text] [Related]
7. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.
Hung CC; Chang WL; Ho JL; Tai JJ; Hsieh TJ; Huang HC; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Jan; 13(2):159-69. PubMed ID: 22188362
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
9. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
Grover S; Gourie-Devi M; Baghel R; Sharma S; Bala K; Gupta M; Narayanasamy K; Varma B; Gupta M; Kaur K; Talwar P; Kaur H; Giddaluru S; Sharma A; Brahmachari SK; Indian Genome Variation Consortium ; Kukreti R
Pharmacogenomics; 2010 Jul; 11(7):927-41. PubMed ID: 20602612
[TBL] [Abstract][Full Text] [Related]
10. [The new algorithm for disease management of patients with epilepsy based on genetic research].
Oros MM; Smolanka VI
Lik Sprava; 2012; (1-2):74-81. PubMed ID: 23035603
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for antiepileptic drug response.
Glauser TA
Biomark Med; 2011 Oct; 5(5):635-41. PubMed ID: 22003912
[TBL] [Abstract][Full Text] [Related]
12. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
[TBL] [Abstract][Full Text] [Related]
13. Gene variants affect response to antiepileptic drugs.
Senior K
Lancet Neurol; 2005 May; 4(5):276-7. PubMed ID: 15861558
[No Abstract] [Full Text] [Related]
14. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression.
Kwan P; Poon WS; Ng HK; Kang DE; Wong V; Ng PW; Lui CH; Sin NC; Wong KS; Baum L
Pharmacogenet Genomics; 2008 Nov; 18(11):989-98. PubMed ID: 18784617
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine approaches in epilepsy.
Walker LE; Mirza N; Yip VLM; Marson AG; Pirmohamed M
J Intern Med; 2015 Feb; 277(2):218-234. PubMed ID: 25338670
[TBL] [Abstract][Full Text] [Related]
17. Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy.
Shaheen U; Prasad DK; Sharma V; Suryaprabha T; Ahuja YR; Jyothy A; Munshi A
Epilepsy Res; 2014 Feb; 108(2):251-6. PubMed ID: 24300029
[TBL] [Abstract][Full Text] [Related]
18. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.
Abe T; Seo T; Ishitsu T; Nakagawa T; Hori M; Nakagawa K
Br J Clin Pharmacol; 2008 Aug; 66(2):304-7. PubMed ID: 18489610
[TBL] [Abstract][Full Text] [Related]
19. [Personalized medicine for epilepsy based on the pharmacogenomic testing].
Yoshida S; Sugawara T; Nishio T; Kaneko S
Brain Nerve; 2011 Apr; 63(4):295-9. PubMed ID: 21441631
[TBL] [Abstract][Full Text] [Related]
20. Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy.
Orlandi A; Paolino MC; Striano P; Parisi P
Expert Opin Drug Metab Toxicol; 2018 May; 14(5):505-512. PubMed ID: 29804481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
